Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H22N8O5 |
Molecular Weight | 454.4393 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@H](CCC(O)=O)C(O)=O
InChI
InChIKey=FBOZXECLQNJBKD-CYBMUJFWSA-N
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6713386
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6713386
METHOTREXATE, (R)- (D-methotrexate) as a contaminant of commercial methotrexate, a chemotherapy agent and immune system suppressant. Methotrexate from various commercial sources has been found to contain 0.5 to 48% (w/w) of the enantiomer D-methotrexate. D-Methotrexate was found to be a good inhibitor of dihydrofolate reductase from both murine and human tumor cells, but was a poor inhibitor of L1210 and CCRF-CEM cell growth. In animal experiments with dogs and mice, D-methotrexate was rapidly absorbed from the intestine and excreted by the kidneys.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL202 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6713386 |
30.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous determination of L- and D-methotrexate using a sequential injection analysis/amperometric biosensors system. | 2003 Nov 30 |
|
Macrocyclic antibiotics as chiral selectors in the design of enantioselective, potentiometric membrane electrodes for the determination of l- and d-enantiomers of methotrexate. | 2004 Sep 8 |
|
[Chiral selectivity in differentiation of lung cancer A549 cell to vascular endothelial cells after drug resistance induced by D-or L-methotrexate enantiomers]. | 2009 Mar 17 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6713386
Dogs: Following p.o. administration of D-methotrexate (1 mg/kg) to the dog, plasma samples were taken at 30, 60, 120, 360 min, and after 24 hr and were analyzed by DHFR inhibition assay.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6713386
The IC50 values determined with
DHFR from L5178Y were 0.7 and 9.1 nM for L-MTX and D-MTX,
respectively. On the other hand, for DHFR from the human
leukemic spleen the respective IC50 values obtained with the L and
D isomers were 0.9 and 30 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1413988
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY | |||
|
DTXSID201317276
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY | |||
|
51865-79-3
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY | |||
|
W12798130R
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY | |||
|
257-482-2
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY | |||
|
72440
Created by
admin on Sat Dec 16 08:24:27 GMT 2023 , Edited by admin on Sat Dec 16 08:24:27 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD